The case for & against
Bull & Bear analysis
Bullish
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a leading biopharmaceutical company that develops innovative therapies focusing on neurological and endocrine disorders. The firm has established a significant market presence with products like Ingresa for tardive dyskinesia and Chronicity for classic congenital adrenal hyperplasia (CAH). Neurocrine is strategically positioned in a growing sector characterized by unmet medical needs, capitalizing on a diverse product pipeline and strong commercial execution.
Bull says
- ↑Q1 2026 product sales jumped 44% YoY, surpassing $800M
- ↑Ingresa revenue hit $657M in Q1, fueled by new patient additions
- ↑Acquired Celeno Therapeutics to target Prader-Willi syndrome and diversify revenue
- ↑25 analyst buy ratings imply 22.8% upside to $194 average target
- ↑Plans for six Phase I and four Phase II trials in 2026 bolster pipeline
- ↑High profitability and liquidity factors underscore financial resilience
Bear says
- ↓Negative book-to-price and dividend yield factors suggest valuation premium
- ↓Emerging CAH therapies and rival tardive dyskinesia treatments threaten market share
- ↓Salesforce expansion may pressure margins if prescription targets underdeliver
- ↓Inflation Reduction Act and payer negotiations could dent Ingresa profitability
- ↓Regulatory and reimbursement shifts heighten execution risks
- ↓Factor vulnerabilities in valuation and capital returns may weigh on stock
Investment themes with NBIX
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Demographics: Elderly Care↓ -0.26%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-08-2026bullish
Transcript signals
Bull points
- We saw a very steady and consistent rate of new patient ads in Q1. With the Salesforce expansion, we expect that we'll be able to build the depth in that prescriber base but also continue to add new prescribers. There's a lot of these patients also that are not under the care of an endocrinologist, and so with our patient-finding efforts, you know, we expect to be able to reach and activate some of those patients this year as well. So feel very good about where we are with the launch of chronicity, and certainly there's a lot of room for organic growth going forward.
- non-GAAP effective tax rate to be between 22% and 24% and within the low 20s going forward.
- At this meeting, we presented new two-year chronicity data from the Phase III Catalyst Adult Study, demonstrating sustained and substantial reductions in glucocorticoid doses in adults with classic congenital adrenal hyperplasia.
Bear points
- we saw that a state of XR has lost preferred coverage with few key plans recently.
- I think on a relative basis, things that are approved for INGREZA, but we wouldn't expect any wide changes out there in terms of reimbursement for INGREZA.
Read full transcript analysis ›